Neuro-Ophthalmology Disorders | PristynCare

Risk Factors

Risk factors for neuro-ophthalmic conditions include:

• Autoimmune disease (multiple sclerosis, lupus, sarcoidosis)
• Vascular disease (hypertension, diabetes, hyperlipidemia)
• History of brain tumors, metastases, or intracranial surgery
• Giant cell arteritis in patients over 50 (risk for AION)
• Pseudotumor cerebri – associated with obesity and certain medications
• Trauma to the head or orbit affecting optic nerves

Who Needs Evaluation

Any patient with unexplained vision loss, optic disc swelling, double vision, visual field defects, or ptosis that does not have a clear primary ocular cause should be referred for neuro-ophthalmic evaluation. Urgent assessment is needed for sudden vision loss, suspected giant cell arteritis, papilledema with headache, or new cranial nerve palsies.

Diagnosis

Neuro-ophthalmic diagnosis involves:

• Visual acuity, color vision, and pupillary response assessment
• Visual field testing (Humphrey perimetry) for field defects
• Optical coherence tomography (OCT) of the optic nerve and ganglion cell layer
• MRI of the brain and orbits with gadolinium contrast
• Fundus photography and fluorescein angiography for optic disc assessment
• Blood tests including ESR, CRP, ANA, ANCA for inflammatory and vascular causes

Treatment Plan

Treatment depends on the underlying diagnosis. Optic neuritis associated with multiple sclerosis is treated with IV methylprednisolone to hasten recovery. Papilledema requires treatment of the underlying cause (tumor resection, CSF diversion for hydrocephalus, or acetazolamide for pseudotumor cerebri). AION from giant cell arteritis requires emergency high-dose systemic steroids. Cranial nerve palsies from diabetes or hypertension usually resolve spontaneously with systemic disease control.

Evaluation and Treatment Steps

The neuro-ophthalmology assessment and management pathway involves:

• Comprehensive ophthalmic examination including best-corrected visual acuity and color vision testing
• Relative afferent pupillary defect (RAPD) testing to identify optic nerve dysfunction
• Slit-lamp examination of the optic disc and anterior segment
• Humphrey visual field testing for field defect mapping
• OCT of the optic nerve head for structural damage assessment
• Urgent MRI brain and orbits ordered when indicated
• Blood tests for ESR, CRP, antinuclear antibodies, and vasculitis markers
• IV methylprednisolone or oral corticosteroids started for inflammatory optic neuropathy
• Neurology referral for workup of demyelinating disease or intracranial pathology

After Treatment Care

Follow-up after neuro-ophthalmic treatment includes:

• Serial visual field testing every 3 to 6 months to monitor progression or recovery
• OCT RNFL monitoring for optic nerve fiber loss over time
• Neurology follow-up for systemic disease management (MS, vasculitis)
• Visual rehabilitation including prisms for persistent diplopia
• Driving and occupation risk assessment in patients with significant field defects
• Annual ophthalmic review for all patients with neuro-ophthalmic conditions

When to Seek Urgent Neuro-Ophthalmic Care

The following situations require urgent or emergency neuro-ophthalmic assessment:

• Sudden painless vision loss: May indicate ischemic optic neuropathy or retinal artery occlusion
• New double vision: May indicate aneurysm, tumor, or cranial nerve palsy
• Headache with vision changes: Papilledema from raised intracranial pressure
• Vision loss with jaw pain or scalp tenderness in elderly patients: Urgent ESR for giant cell arteritis
• Progressive visual field loss: May indicate pituitary tumor or other compressive lesion
• Transient vision loss (amaurosis fugax): May indicate carotid artery disease requiring urgent vascular workup